Author/Authors :
Lohr، نويسنده , , Miriam and Edlund، نويسنده , , Karolina and Botling، نويسنده , , Johan and Hammad، نويسنده , , Seddik and Hellwig، نويسنده , , Birte and Othman، نويسنده , , Amnah and Berglund، نويسنده , , Anders and Lambe، نويسنده , , Mats A. Holmberg، نويسنده , , Lars and Ekman، نويسنده , , Simon and Bergqvist، نويسنده , , Michael and Pontén، نويسنده , , Fredrik and Cadenas، نويسنده , , Cristina and Marchan، نويسنده , , Rosemarie and Hengstler، نويسنده , , Jan G. and Rahnenführer، نويسنده , , Jِrg and Micke، نويسنده , , Patrick، نويسنده ,
Abstract :
A prognostic impact of immunoglobulin kappa C (IGKC) expression has been described in cancer. We analysed the influence of B-cell and plasma cell markers, as well as IGKC expression, in non-small lung cancer (NSCLC) using immunohistochemistry on a tissue microarray. IGKC protein expression was independently associated with longer survival, with particular impact in the adenocarcinoma subgroup. Moreover, a correlation was seen with CD138+ cells, but not with CD20. CD138 expression revealed a comparable association with survival. In conclusion, IGKC expression in stroma–infiltrating plasma cells is a prognostic marker in NSCLC, supporting emerging treatment concepts that exploit the humoral immune response.
Keywords :
Tumour immunity , Microarray , Prognosis , Biomarker
